王昌平,黄珣,李勇军,黄维,杨丽

• 1:宜宾市第一人民医院肿瘤科

摘要(Abstract)：

目的探讨多西他赛与培美曲塞分别联合铂类治疗吉非替尼治疗失败NSCLC患者的疗效及不良反应。方法选取吉非替尼治疗失败NSCLC患者110例,随机数字法分为A组(n=55)和B组(n=55),分别在铂类应用基础上加用多西他赛或培美曲塞辅助治疗。比较两组患者近期疗效、总生存、无进展生存、EORTC QLQ-C30评分和KPS评分改变以及严重不良反应发生率等。结果两组患者客观缓解率(objective response rate,ORR)和疾病控制率(disease control rate,DCR)比较差异均无统计学意义(均P>0.05)。B组患者无进展生存时间长于A组,差异具有统计学意义(P<0.05)。两组总生存时间比较差异无统计学意义(P>0.05)。两组治疗后EORTC QLQC30评分和KPS评分均高于治疗前,且B组治疗后各项评分高于A组(均P<0.05)。B组Ⅲ~Ⅳ级白细胞减少、血红蛋白减少、血小板减少、恶心呕吐、皮疹及肝功能损伤发生率低于A组(均P<0.05);两组Ⅲ~Ⅳ级腹泻和脱发发生率比较差异均无统计学意义(均P>0.05)。结论多西他赛或培美曲塞联合铂类治疗吉非替尼治疗失败NSCLC患者疗效接近,但培美曲塞联合铂类方案可有效延长无进展生存时间,提高生活质量,以及减少严重不良反应发生。

关键词(KeyWords)： 癌,非小细胞肺/药物疗法;紫杉烷类/投药和剂量;谷氨酸盐类;鸟嘌呤/类似物和衍生物;鸟嘌呤/投药和剂量;顺铂/投药和剂量;抗肿瘤联合化疗方案/治疗应用;随机对照试验;治疗结果

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王昌平,黄珣,李勇军,黄维,杨丽

DOI: 10.13267/j.cnki.syzlzz.2017.02.014

参考文献(References)：

• [1]朱婷,鲍杨漪,江茜,等.盐酸埃克替尼治疗老年晚期非小细胞肺癌患者的临床观察[J].实用肿瘤杂志,2014,29(3):259-262.
• [2]Villano JL,Durbin EB,Normandeau C,et al.Incidence of brain metastasis at initial presentation of lung cancer[J].Neuro Oncol,2015,17(1):122-128.
• [3]Mesago K,Fujita S,Togashi Y,et al.Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy[J].Clin Lung Cancer,2011,12(1):56-61.
• [4]Iwasaki K,Osaka Y,Tachibana S,et al.PhaseⅠStudy of docetaxel,cisplatin,and 5-fluorouracil chemoradiotherapy for local or metastatic esophageal cancer[J].Anticancer Res,2016,36(3):987-994.
• [5]孙燕.内科肿瘤学[M].北京:人民卫生出版社,2001:996.
• [6]李进.肿瘤内科诊治策略[M].上海:上海科学技术出版社,2007:50.
• [7]于韶荣,史美祺,夏国豪,等.贝伐珠单抗联合含铂化疗方案一线治疗晚期非鳞NSCLC疗效分析[J].实用肿瘤杂志,2015,30(5):418-422.
• [8]D'Antonio C,Passaro A,Gori B,et al.Bone and brain metastasis in lung cancer:recent advances in therapeutic strategies[J].Ther Adv Med Oncol,2014,6(3):101-114.
• [9]Choi MK,Hong JY,Chang WJ,et al.A phaseⅡtrial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations:implications of sensitive EGFR mutation test[J].Cancer Chemother Pharmacol,2015,75(6):1229-1236.
• [10]Karayama M,Inui N,Fujisawa T,et al.Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin,pemetrexed,and bevacizumab in patients with advanced non-squamous non small cell lung cancer[J].Eur J Cancer,2016,58(6):30-37.
• [11]Li S,Zhou F,Ren S,et al.Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC[J].Lung Cancer,2014,84(2):203-205.
• [12]Mesago K,Fujita S,Togashi Y,et al.Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy[J].Clin Lung Cancer,2011,12(1):56-61.
• [13]Wu M,Yuan Y,Pan YY,et al.Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive,primary resistant and acquired resistant human non-small cell lung cancer cells[J].Mol Med Rep,2014,9(6):2417-2422.
• [14]Tièche CC,Peng RW,Dorn P,et al.Prolonged pemetrexed pre-treatment augments persistence of cisplatininduced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT[J].BMC Cancer,2016,16(1):1-15.